UNSPSC 51373415: Brompheniramine/codeine/guaifenesin/phenylephrine/phenylpropanol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373415 Brompheniramine/codeine/guaifenesin/phenylephrine/phenylpropanol is a Commodity code covering branded and generic combination cough, cold, and allergy medications in multi-ingredient formulations. State and local governments procure this code primarily as part of broader pharmaceutical supply agreements for public health departments, emergency management agencies, and community health facilities. The issuing bodies range from county health departments and cooperative purchasing alliances to state pharmaceutical procurement offices, often bundling this Commodity with other generic multi-source drugs and over-the-counter products into comprehensive supply contracts.

Recent activity centers on cooperative purchasing vehicles and direct county procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 due March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026 and vendor products required to be available by May 15, 2026. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) seeking naloxone and drug deactivation systems for community health initiatives with quarterly deliveries to the county's Community Health Building in Sanford. While the Seminole County opportunity focuses on naloxone rather than the specific combination cough medication this code nominally describes, the MMCAP RFP reflects genuine activity in multi-ingredient pharmaceutical procurement across the upper Midwest and Pacific Northwest. Geographic spread of recent solicitations centers on Minnesota (through MMCAP's multi-state membership) and Florida, with MMCAP's scope extending to Oregon. The cooperative purchasing model dominates current market activity, with vendors required to demonstrate cGMP certification, DSCSA compliance, contractual relationships with authorized wholesalers, and flexible pricing options including flat-fee, net-price, and WAC-minus structures.